JG
SWTX

Jefferies Group’s SpringWorks Therapeutics SWTX Stock Holding History

Jefferies Group’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-141,900
Closed -$8.01M – 1841
2022
Q1 		$8.01M Buy
+141,900
New +$8.12M 0.05% 283

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Jefferies Group's SWTX Position: Q3 2022 in Review

Jefferies Group opened a new position in SpringWorks Therapeutics (SWTX) in Q3 2022: 12,060 shares worth $344K. The stake represents ﹤0.01% of the portfolio and ranks #1177 among its holdings. This is a return to the name: Jefferies Group previously reported a position in SWTX as recently as Q1 2022.

Jefferies Group first reported a position in SWTX in Q1 2022 and has held it in 2 quarters since. The position peaked at $660K in Q1 2022. 148 funds tracked by Wall St. Rank hold SWTX as of Q3 2022.

  • Jefferies Group held 12,060 shares of SpringWorks Therapeutics worth $344K as of Q3 2022.
  • SpringWorks Therapeutics was a new Jefferies Group position in Q3 2022.
  • SpringWorks Therapeutics made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1177 holding.
  • Jefferies Group first reported a position in SpringWorks Therapeutics in Q1 2022 and has held it in 2 quarters since.
  • Jefferies Group's SpringWorks Therapeutics position peaked at $660K in Q1 2022.
  • 148 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.